Investigational drug · Phase 3
Cenerimod
Also called: ACT-334441
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lupus Erythematosus, Systemic, SLE - Systemic Lupus Erythematosus, Nephritis, Lupus.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
13
Any phase or sponsor naming "Cenerimod"
First trial start
2022
Dec 13, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cenerimod", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lupus Erythematosus, Systemic
- SLE - Systemic Lupus Erythematosus
- Nephritis, Lupus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Cenerimod" as an intervention, largest first.
- Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusPivotal-lookingEnrolling by invitation
Viatris Innovation GmbHIndustry
NCT06475742 · 680 participants (planned) · Start Jul 30, 2024 · Primary completion Sep 2032
Drug: Cenerimod · For: Lupus Erythematosus, Systemic
Sites: Aurora, Colorado; Clearwater, Florida; DeBary, Florida · 122 sites in all
- A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
Viatris Innovation GmbHIndustry
NCT05648500 · 470 participants · Start Dec 13, 2022 · Primary completion Mar 31, 2027
Drug: Cenerimod; Placebo · For: Lupus Erythematosus, Systemic
Sites: Huntington Park, California; Aurora, Colorado; Clearwater, Florida · 198 sites in all
- A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
Viatris Innovation GmbHIndustry
NCT05672576 · 451 participants · Start Jun 26, 2023 · Primary completion Dec 31, 2026
Drug: Cenerimod; Placebo · For: Lupus Erythematosus, Systemic
Sites: Tucson, Arizona; La Jolla, California; Northridge, California · 147 sites in all
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusPivotal-lookingCompleted
Viatris Innovation GmbHIndustry
NCT03742037 · 427 participants · Start Dec 21, 2018 · Primary completion Aug 31, 2021
Drug: Cenerimod 0.5 mg; Cenerimod 1 mg and 4 more · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; La Jolla, California; Los Alamitos, California · 148 sites in all
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentPivotal-lookingRecruiting
Viatris Innovation GmbHIndustry
NCT07201129 · 300 participants (planned) · Start Feb 9, 2026 · Primary completion Aug 2029
Drug: Cenerimod; Placebo · For: Nephritis, Lupus; Lupus Erythematosus, Systemic
Sites: Doral, Florida; Kissimmee, Florida; Miami, Florida · 14 sites in all
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus ErythematosusPivotal-lookingCompleted
Viatris Innovation GmbHIndustry
NCT02472795 · 105 participants · Start Jun 1, 2015 · Primary completion Jan 23, 2017
Drug: Matching placebo; Cenerimod · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Clearwater, Florida; Minsk, Belarus · 18 sites in all
Viatris Innovation GmbHIndustry
NCT04255277 · 97 participants · Start Jan 31, 2020 · Primary completion Sep 14, 2021
Drug: Combined oral contraceptives (COC); Moxifloxacin 400mg and 3 more · For: Healthy Subjects
Sites: Rennes, France
Viatris Innovation GmbHIndustry
NCT04819464 · 24 participants · Start Aug 25, 2021 · Primary completion Aug 18, 2024
Drug: Cenerimod · For: Healthy; Hepatic Impairment
Sites: Kistarcsa, Hungary; Porto, Portugal
Viatris Innovation GmbHIndustry
NCT04052360 · 20 participants · Start Aug 7, 2019 · Primary completion Oct 29, 2019
Drug: Cenerimod; Matching Placebo · For: Healthy Volunteers
Sites: Anaheim, California
Viatris Innovation GmbHIndustry
NCT05004311 · 16 participants · Start Sep 27, 2021 · Primary completion Jul 27, 2023
Drug: Cenerimod · For: Healthy; Renal Impairment
Sites: Porto, Portugal
Newest research
PubMed records naming it or its code names, newest first.
- Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis.
Li W, Zhao Y, Shu S, et al. · Front Immunol 2026
- Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE.
Suffiotti M, Brazauskas P, Keller MP, et al. · Ann Rheum Dis 2025
- Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
Askanase AD, D'Cruz D, Kalunian K, et al. · Lancet Rheumatol 2025
- Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.
Kaye AD, Tassin JP, Upshaw WC, et al. · Cureus 2024
- The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives.
Schwalm S, Manaila R, Oftring A, et al. · Pflugers Arch 2024
- Multiple-dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination.
Mueller MS, Juif PE, Charfi H, et al. · J Clin Pharmacol 2024
Also in development for Lupus Erythematosus, Systemic
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- LitifilimabBIIB059Phase 35 trials
Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.